CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
Authors
Keywords
PD-1, PD-L1, T cell cytotoxicity, CEA BiTE, Immunotherapy
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 64, Issue 6, Pages 677-688
Publisher
Springer Nature
Online
2015-03-05
DOI
10.1007/s00262-015-1671-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients
- (2014) X Wu et al. BRITISH JOURNAL OF CANCER
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Notch signaling regulates PD-1 expression during CD8+ T-cell activation
- (2012) Mélissa Mathieu et al. IMMUNOLOGY AND CELL BIOLOGY
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
- (2010) Mona Karlsson et al. ANNALS OF SURGICAL ONCOLOGY
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
- (2009) T Osada et al. BRITISH JOURNAL OF CANCER
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
- (2009) Ralf Lutterbuese et al. JOURNAL OF IMMUNOTHERAPY
- Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells
- (2008) S. Nagaraj et al. CANCER RESEARCH
- Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infection
- (2008) Sang-Jun Ha et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now